@article {1832, title = {Heart transplantation using donors positive for hepatitis.}, volume = {36}, year = {2004}, note = {Status: MEDLINE; Publishing Model: Journal available in: Print Citation processed from: Print; NLM Journal Code: we9, 0243532}, month = {Oct}, pages = {1}, address = {United States}, abstract = {From May 1994 to September 2003, 177 hearts were procured for heart transplantation (HTx) from donors ranging in age from 1 year 2 months to 66 years 5 months (mean = 30 years). All donors and recipients received serologic tests for hepatitis B surface antigen (HBsAg) and antibody (anti-HBs), and hepatitis C virus antibody (anti-HCV). Thirty-two donors were HBsAg-positive and another four were anti-HCV-positive. Two HBsAg-positive donors were transplanted to patients with no previous evidence of hepatitis. After HTx, one received hepatitis B immunoglobulin prophylaxis and no hepatitis was noted during a 5 years follow-up. The other seroconverted at 4 months after HTx, requiring lamivudine treatment. Another four HBsAg-positive donors were transplanted to HBsAg-positive recipients. All four recipients had hepatitis flare-ups requiring lamivudine treatment. The other 26 HBsAg-positive donors were transplanted to anti-HBs-positive recipients. None suffered from hepatitis. Among the four patients receiving anti-HCV-positive hearts, seroconversion was noted in one recipient at 26 months. This patient never had clinical hepatitis before he died of allograft rejection at 3 years after HTx. The other three recipients remain anti-HCV negative during follow-up of 80, 50, and 46 months. It was concluded the hepatitis B- or C-positive donors could be used as heart donors for status 1 patients. Donors with positive HBsAg may be transplanted to anti-HBs-positive recipients with no HBV infection.}, keywords = {Adolescent, Adult, Antiviral Agents / tu [Therapeutic Use], Brain Death, Cause of Death, Child, Child, Preschool, Female, Heart Transplantation / ph [Physiology], Heart Transplantation / sn [Statistics \& Numerical Data], Hepatitis B / ep [Epidemiology], Hepatitis B Surface Antigens / bl [Blood], Hepatitis C / ep [Epidemiology], Humans, IM, Infant, Lamivudine / tu [Therapeutic Use], Male, Middle Aged, Retrospective Studies, Tissue Donors / sn [Statistics \& Numerical Data]}, issn = {0041-1345; 0041-1345}, author = {Wang,S. S. and Chou,N. K. and Ko,W. J. and Yu,H. Y. and Chen,Y. S. and Hsu,R. B. and Huang,S. C. and Chi,N. H. and Tsao,C. I. and Lai,M. Y. and Liau,C. S. and Lee,Y. T.} }